Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Why invest in FBDU?

Flying Brands on track for successful commercial roll-out of StoneChecker

“We look forward to the future with confidence and excitement," said Flying Brands boss Trevor Brown.
Flying Brands
The StockChecker software provides a detailed analysis of kidney stones

Flying Brands Ltd (LON:FBDU) is inching closer towards the global commercial roll-out of its key kidney stone medical imaging software StoneChecker.

The company is awaiting clearance from the US Food and Drug Administration for StoneChecker, which is expected by the third quarter.

Once approved, the group aims to launch the software in the US, India and China by the end of the year while commercial sales in the UK are expected to begin in the fourth quarter.

A commercial version of the cloud-based interface is scheduled for the third quarter.

To support the commercial roll-out of the kidney stone analysis programme, Flying Brands recently raised £500,000 in a share placement.

StoneChecker received European CE clearance last December, paving the way for the commercial application of the software.  

Flying Brands secures contract for StoneChecker

In March, Flying Brands secured its first major marketing and distribution contract for StoneChecker – with Korea Computer Motion ISG, which is selling the software in South Korea.

Recently acquired Imaging Biometrics (IB), which specialises in applying machine learning and artificial intelligence to imaging, has been managing the process for both FDA and European CE clearance.

Other deals 

Since taking full ownership of IB in March, the business has been busy making deals and forging partnerships. 

One of the deals is a distribution agreement with artificial intelligence exchange platform EnvoyAI. IB Neuro, which measures blood volume in the brain, and the Delta T1 mapping algorithm, are now available for purchase on the exchange.

IB has also partnered up with cloud-based platform QMENTA, which provides data analysis and management for neuro experts. IB will load its software onto QMETNA and believes this will “accelerate neuroscience research and increase accuracy in diagnostics support".

In another partnership, IB is providing access to its quantitative software on the platform of medical imaging company Medimsight. This allows physicians and researchers to purchase IB's technologies without the need for any specific IT infrastructure.

Researchers using Imaging Biometrics software

Meanwhile, IB’s software has caught the attention of researchers in the US and Greece.

Its Rad Tech software will be used in a large phase II brain cancer study by the American College of Radiology Imaging Network (ACRIN).

The software will help quantify how patients are responding to Avastin (bevacizumab) – a common cancer medication.

The General Anti-Cancer and Oncological Hospital, a leading medical centre in Athens, is also planning to roll out a suite of the company's products, including IB Rad Tech, to guide the treatment of patients with brain tumours.

“The acquisition of IB represents the first step in the execution of our vision to become a significant participant in the field of medical imaging diagnostics and the application of artificial intelligence in medical imaging,” said chief executive Trevor Brown.

“We look forward to the future with confidence and excitement.”

View full FBDU profile View Profile

Flying Brands Ltd Timeline

Related Articles

Flying Brands
July 17 2018
“We look forward to the future with confidence and excitement," said Flying Brands boss Trevor Brown.
H&T Pawnbrokers store
July 02 2018
Last year the company saw gross profits jump 45% thanks to a booming personal loan book and robust sales of luxury second-hand watches and jewellery.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use